NSRX

Nasus Pharma Ltd.

Nasus Pharma is a clinical-stage specialty pharmaceutical company focused primarily on the development of intranasal drugs to treat emergency medical conditions such as severe allergies, anaphylaxis, and opioid overdose. Their lead products include NS002, an intranasal powder epinephrine nasal spray for type 1 severe allergies and anaphylaxis, and NS001, an intranasal naloxone powder spray for opioid overdose. They use a powder-based intranasal technology that offers rapid drug absorption.

Nasus Pharma Ltd. (NSRX) is rated C- (2.1/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Profitability (D-).

Quantitative Factor Evaluation • Updated

Overall Rating
2.1 / 5.0
C-
Value
C+
Factor Score 2.5 / 5.0
Growth
D+
Factor Score 1.8 / 5.0
Profitability
D-
Factor Score 0.8 / 5.0
Momentum
C
Factor Score 2.5 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio N/A
EV / EBITDA N/A
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -22.1%
Price Return 12M -62.4%
Catalyst Signal 0.00
Market Cap $33.0M
TTM Revenue N/A
Price / Sales N/A
ROE -316.0%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-13 C+ (2.5) D+ (1.8) D- (0.8) C (2.5) C+ (2.6) C- (2.1)
2026-11-06 C+ (2.5) D+ (1.8) D- (0.8) C+ (2.7) C+ (2.7) C- (2.1)
2026-10-30 C+ (2.5) D+ (1.8) D- (1.0) B- (3.1) C+ (2.7) C (2.2)
2026-10-23 C+ (2.5) C- (1.9) D- (0.9) C+ (2.7) C+ (2.6) C- (2.1)
2026-10-16 C+ (2.5) D+ (1.8) D- (0.9) B (3.2) C+ (2.6) C (2.2)
Page 1 of 3